Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare 2 Formulations of LY900014 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study~* Have veins suitable for easy blood collection and glucose solution infusion~Exclusion Criteria:~- Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study~* Had donated blood of more than 450 milliliters (mL) or participated in a clinical trial with similar blood loss within the last 3 months~* Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female)~* Smoke more than 10 cigarettes per day~* Are infected with hepatitis B or human immunodeficiency virus (HIV)~* Are taking illegal drugs

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 U-200 (Type: EXPERIMENTAL): Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
- LY900014 U-100 (Type: EXPERIMENTAL): Single SC dose of LY900014 U-100 in two of four study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).